Loading UTHR detail
Loading ticker data...
Loading UTHR detail
United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally.
Its commercial therapies include Remodulin to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Tyvaso, an inhaled formulation of prostacyclin analogue treprostinil to enhance the exercise ability in PAH patients and pulmonary hypertension associated with interstitial lung disease (PH-ILD); Orenitram, a tablet dosage form of treprostinil to enhance the exercise capacity in PAH patients; Unituxin, a monoclonal antibody for treating high-risk neuroblastoma; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients. The company also engages in developing Tyvaso DPI, a dry powder inhalation form of Tyvaso; Remunity Pump, a small, lightweight, durable pump and separate controller; RemoPro and Ralinepag for the treatment of PAH; Aurora-GT, a gene therapy product to rebuild the blood vessels in the lungs; and Tyvaso PERFECT and TETON studies, which are the studies of Tyvaso in patients with World Health Organization (WHO) Group 3 pulmonary hypertension associated with chronic obstructive pulmonary disease (PH-COPD). It has licensing and collaboration agreements with DEKA Research & Development Corp. to develop a semi-disposable system for the subcutaneous delivery of treprostinil; MannKind Corporation to develop and license treprostinil inhalation powder and the Dreamboat device; and Arena Pharmaceuticals, Inc. to develop Ralinepag.
The company was incorporated in 1996 and is headquartered in Silver Spring, Maryland.
Chart data unavailable
Pre-Market Stock Futures: The futures are trading mixed as we approach the end of one of the most volatile and wild trading weeks in recent memory. After starting the day lower on Thursday as mixed reports on the success of the ships passing through the Strait of Hormuz rolled in, stocks gained momentum as the... Here Are Friday's Top Wall Street Analyst Research Calls: Autodesk, Delek US Holdings, Insmed, Nike, Nutanix, ServiceNow, Shake Shack, Southern Copper, Veeva Systems, and More
United Therapeutics Corporation (NASDAQ: UTHR - Get Free Report) CEO Martine Rothblatt sold 9,500 shares of the firm's stock in a transaction that occurred on Monday, April 6th. The stock was sold at an average price of $558.41, for a total transaction of $5,304,895.00. Following the transaction, the chief executive officer directly owned 40,513 shares of
United Therapeutics Corporation (NASDAQ: UTHR - Get Free Report) CFO James Edgemond sold 10,000 shares of United Therapeutics stock in a transaction on Monday, April 6th. The shares were sold at an average price of $558.40, for a total transaction of $5,584,000.00. Following the completion of the sale, the chief financial officer owned 18,876 shares in
SILVER SPRING, Md. & RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--United Therapeutics Corporation (Nasdaq: UTHR), a public benefit corporation, today announced that the U.S. Food and Drug Administration (FDA) has granted Regenerative Medicine Advanced Therapy (RMAT) designation to the company's investigational miroliverELAP®, an external liver assist product. Developed by Miromatrix Medical Inc., a wholly owned subsidiary of United Therapeutics, miroliverELAP consists of an external blood cir.
Guru Stock PicksBrandes Investment Partners, LP has made the following transactions:Add in KMT by 0.94%Stock News Stocks steady into Iran deadline: The S&P 500
BAM Wealth Management LLC purchased a new position in United Therapeutics Corporation (NASDAQ: UTHR) during the undefined quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor purchased 886 shares of the biotechnology company's stock, valued at approximately $432,000. Other hedge funds have
Element Squared LLC bought a new position in shares of United Therapeutics Corporation (NASDAQ: UTHR) during the undefined quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor bought 5,027 shares of the biotechnology company's stock, valued at approximately $2,449,000. United Therapeutics accounts for 1.3%
United Therapeutics (UTHR) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
Investors interested in stocks from the Medical - Drugs sector have probably already heard of Catalyst Pharmaceutical (CPRX) and United Therapeutics (UTHR). But which of these two stocks offers value investors a better bang for their buck right now?
United Therapeutics Corporation (NASDAQ: UTHR - Get Free Report) EVP Paul Mahon sold 8,300 shares of the business's stock in a transaction on Thursday, April 2nd. The stock was sold at an average price of $565.87, for a total value of $4,696,721.00. Following the transaction, the executive vice president directly owned 45,172 shares of the company's
United Therapeutics Corporation (NASDAQ: UTHR - Get Free Report) CFO James Edgemond sold 10,000 shares of United Therapeutics stock in a transaction dated Monday, March 30th. The stock was sold at an average price of $593.17, for a total transaction of $5,931,700.00. Following the sale, the chief financial officer directly owned 18,876 shares of the company's
United Therapeutics Corporation (NASDAQ: UTHR - Get Free Report) CEO Martine Rothblatt sold 9,500 shares of the stock in a transaction dated Wednesday, April 1st. The stock was sold at an average price of $581.63, for a total value of $5,525,485.00. Following the completion of the sale, the chief executive officer directly owned 40,513 shares of
United Therapeutics Corporation (NASDAQ: UTHR - Get Free Report) CEO Martine Rothblatt sold 9,500 shares of the stock in a transaction that occurred on Monday, March 30th. The stock was sold at an average price of $590.59, for a total transaction of $5,610,605.00. Following the transaction, the chief executive officer directly owned 40,513 shares of the
Brookstone Capital Management grew its position in shares of United Therapeutics Corporation (NASDAQ: UTHR) by 25.4% in the undefined quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 6,622 shares of the biotechnology company's stock after purchasing an additional 1,342 shares during the quarter. Brookstone
United Therapeutics Corporation maintains a Strong Buy rating after a second phase 3 win for nebulized Tyvaso in idiopathic pulmonary fibrosis [IPF]. UTHR achieved superior FVC improvement in TETON-1 [130.1 mL] versus TETON-2 [95.6 mL], both statistically significant, supporting sNDA submission for IPF by summer of this year. Priority Review will be sought for Tyvaso in IPF, with further expansion targeted via ongoing TETON-PPF for progressive pulmonary fibrosis.
